Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283900 · ClinicalTrials.gov registry record · Phase 2
Ascorbate in Myelodysplastic Syndrome
A Phase 2 study of Myelodysplastic Syndromes, sponsored by Prajwal Dhakal.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT07283900 is a Phase 2 study of Myelodysplastic Syndromes that is actively recruiting participants, run by Prajwal Dhakal. The registered enrollment target is 38 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07283900, a Phase 2 study of Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Prajwal Dhakal.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
Conditions Studied
Interventions
- DRUG Azacitidine
- DRUG High-dose ascorbate
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2029-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07283900
The ClinicalTrials.gov registry entry for NCT07283900 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (87% lower). The listed sponsor is Prajwal Dhakal, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Azacitidine is the first listed.
NCT07283900 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT07283900 about?
NCT07283900 is a clinical study titled "Ascorbate in Myelodysplastic Syndrome". This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
What is the current status of trial NCT07283900?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2026-03-11. Estimated completion is 2029-05-01.
What conditions does trial NCT07283900 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes.
What interventions are being tested in trial NCT07283900?
The interventions under investigation include: Azacitidine (DRUG), High-dose ascorbate (DRUG).
Who is sponsoring clinical trial NCT07283900?
This trial is sponsored by Prajwal Dhakal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07283900 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.